English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Pro

Presents the zaia usage as premium feature

ZAIA

Presents AI Discovery search usage as a premium feature

AI Discovery

Presents AI Discovery explain and summary usage as a premium feature

Content Analysis

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Presents the pdf analysis as premium feature

PDF Analysis

1500 Top-up

3000 Top-up

Zendy Basic

2500 Top-up

Zendy Unlimited

Presents the access of premium content as premium feature

Premium Content

Clinical outcomes of chemotherapy for patients with advanced pancreatic adenocarcinoma in a real-world setting might differ from outcomes in randomized clinical trials (RCTs). Here we show in a single-institution cohort of 595 patients that median overall survival (OS) of patients who received gemcitabine alone ( n = 185; 6.6 months (95% CI; 5.5-7.7)) was the same as in pivotal RCTs. Gemcitabine/capecitabine ( n = 60; 10.6 months (95% CI; 7.8-13.3)) and gemcitabine/nab-paclitaxel ( n = 66; 9.8 months (95% CI; 7.9-11.8)) resulted in a longer median OS and fluorouracil/oxaliplatin/irinotecan ( n = 31, 9.9 months (95% CI; 8.1-11.7)) resulted in a shorter median OS than previously reported. Fluorouracil/oxaliplatin ( n = 35, 5.8 months (95% CI; 4.5-7)) and best supportive care ( n = 206, 1.8 months (95% CI; 1.5-2.1)) could not be benchmarked against any RCTs. The degree of protocol adherence explained differences between real-world outcomes and the respective RCTs, while exposure to second-line treatments did not.

Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort